
AlloVir ALVR
Quarterly report 2025-Q3
added 11-12-2025
AlloVir Total Current Liabilities 2011-2026 | ALVR
Annual Total Current Liabilities AlloVir
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.24 M | 28.4 M | 24.3 M | 37.9 M | 12.3 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 37.9 M | 5.24 M | 21.6 M |
Total Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Acer Therapeutics
ACER
|
19 M | - | 2.71 % | $ 14 M | ||
|
Acasti Pharma
ACST
|
1.93 M | - | 4.01 % | $ 150 M | ||
|
Anavex Life Sciences Corp.
AVXL
|
5.04 M | $ 4.13 | 5.36 % | $ 352 M | ||
|
I-Mab
IMAB
|
576 M | - | - | $ 866 M | ||
|
Adverum Biotechnologies
ADVM
|
22.9 M | - | - | $ 86.2 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
25.2 M | - | - | $ 26.5 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
1.62 B | - | - | $ 40.3 B | ||
|
Adagene
ADAG
|
38.2 M | $ 3.19 | 11.93 % | $ 180 M | ||
|
Akouos
AKUS
|
16.8 M | - | 0.23 % | $ 488 M | ||
|
Aptorum Group Limited
APM
|
4.34 M | $ 0.71 | -16.82 % | $ 3.87 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
1.77 M | - | -1.52 % | $ 24.7 M | ||
|
Ampio Pharmaceuticals
AMPE
|
2.38 M | - | -11.43 % | $ 502 K | ||
|
Biogen
BIIB
|
3.35 B | $ 197.56 | 1.05 % | $ 28.9 B | ||
|
Bristol-Myers Squibb Company
BMY
|
23.4 B | $ 60.75 | 1.49 % | $ 124 B | ||
|
Applied Molecular Transport
AMTI
|
15.1 M | - | - | $ 10.1 M | ||
|
ARCA biopharma
ABIO
|
13 M | - | 1052.0 % | $ 415 M | ||
|
Acorda Therapeutics
ACOR
|
228 M | - | -24.86 % | $ 820 K | ||
|
Aptose Biosciences
APTO
|
4.46 M | - | -45.71 % | $ 1.2 M | ||
|
Akero Therapeutics
AKRO
|
39.8 M | - | - | $ 3.67 B | ||
|
Athira Pharma
ATHA
|
13.1 M | - | - | $ 269 M | ||
|
Aeglea BioTherapeutics
AGLE
|
54.1 M | - | - | $ 1.01 B | ||
|
Albireo Pharma
ALBO
|
45.3 M | - | -0.23 % | $ 916 M | ||
|
Институт стволовых клеток человека
ISKJ
|
556 M | - | - | - | ||
|
Allena Pharmaceuticals
ALNA
|
15.7 M | - | 3.16 % | $ 1.9 M | ||
|
Aptinyx
APTX
|
6.29 M | - | -39.0 % | $ 4.57 M | ||
|
Aravive
ARAV
|
22.1 M | - | -13.39 % | $ 1.45 M | ||
|
Arena Pharmaceuticals
ARNA
|
66.3 M | - | -6.81 % | $ 3.04 B | ||
|
Aridis Pharmaceuticals
ARDS
|
36.9 M | - | 17.91 % | $ 11.1 M | ||
|
Brickell Biotech
BBI
|
1.66 M | - | -5.38 % | $ 6.06 M | ||
|
AgeX Therapeutics
AGE
|
5.91 M | - | -10.17 % | $ 12.2 K | ||
|
Athersys
ATHX
|
29.9 M | - | 3.77 % | $ 22.4 M | ||
|
Corcept Therapeutics Incorporated
CORT
|
141 M | $ 40.16 | 4.73 % | $ 4.15 B | ||
|
Avenue Therapeutics
ATXI
|
816 K | - | -52.27 % | $ 4.45 M | ||
|
BeiGene, Ltd.
BGNE
|
2.21 B | - | 0.49 % | $ 251 B | ||
|
Autolus Therapeutics plc
AUTL
|
60.7 M | $ 1.42 | 2.9 % | $ 362 M | ||
|
Amneal Pharmaceuticals
AMRX
|
1.13 B | $ 14.91 | 1.92 % | $ 4.61 B | ||
|
CRISPR Therapeutics AG
CRSP
|
149 M | $ 53.36 | 9.05 % | $ 4.8 B | ||
|
AIkido Pharma
AIKI
|
3.78 M | - | 1.93 % | $ 17.4 M | ||
|
AVROBIO
AVRO
|
6.35 M | - | 1083.1 % | $ 745 M |